Source catalogue

Sources

Everything this site claims points at something on this page. Each entry says what it supports and when it was last opened and confirmed.

By Evan Marsh · Updated

Sources are ranked in a fixed hierarchy, and a lower-tier source never overrides a higher one. If a press release and the FDA's own database disagree about approval status, the database wins and the disagreement gets reported.

  1. Tier 1
    Regulator — FDA and equivalent agencies — approval records, warning letters, guidance.
  2. Tier 2
    Trial registry — ClinicalTrials.gov entries, which the sponsor is legally required to keep current.
  3. Tier 3
    Sponsor disclosure — Eli Lilly press releases, investor materials and SEC filings.
  4. Tier 4
    Peer-reviewed literature — Journal publications that have been through external review.

Tier 1Regulator

  • Drugs@FDA: FDA-Approved Drugs

    U.S. Food and Drug Administration · Checked July 30, 2026

    Retatrutide has no approval record. A search of Drugs@FDA and of the openFDA drug application API returns no match for retatrutide or for LY3437943.

  • openFDA drug application API — retatrutide query

    U.S. Food and Drug Administration · Checked July 30, 2026

    A query for retatrutide against the Drugs@FDA dataset returns NOT_FOUND, which is the machine-readable form of the same fact: there is no FDA drug application record for retatrutide.

  • Warning Letter — Gram Peptides (MARCS-CMS 721806)

    U.S. Food and Drug Administration · Published March 31, 2026 · Checked July 30, 2026

    FDA describes retatrutide products offered for sale online as unapproved new drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act, notwithstanding 'research use only' labelling.

Tier 2Trial registry

  • ClinicalTrials.gov — retatrutide studies

    U.S. National Library of Medicine · Checked July 30, 2026

    The registry set of retatrutide studies, their recruitment status, enrolment and dates.

  • NCT07629401 — Provide Pre-approval Expanded Access of Retatrutide

    U.S. National Library of Medicine · Checked July 30, 2026

    Eli Lilly has an expanded access record for retatrutide with a listed status of Available. Expanded access is a regulated pathway operated by the sponsor and a treating physician; it is not a prescription and not a commercial supply.

Tier 3Sponsor disclosure

Tier 4Peer-reviewed literature

What is not used as a source

Secondary coverage is used to learn that something happened, and then the primary document is retrieved and read. A news article is never cited as the basis for a status on this site.

Analyst notes, price targets, forum posts, social media, and vendor websites are not sources. Neither is another tracker. If a claim cannot be traced to a regulator, a registry, the sponsor or the peer-reviewed literature, it does not appear here — even when it is probably true.

One live example: several outlets described Lilly's Q1 2027 filing window as a delay from earlier guidance. No primary Lilly source stating earlier guidance could be located, so this site does not describe it as a delay.

How often sources are re-checked

The FDA approval record and the primary Lilly newsroom are checked on a regular cadence, and every check updates the timestamp shown in the status card whether or not anything changed. Trial registry entries are re-checked when a trial is expected to complete or read out. The dates on this page are the dates each source was actually opened.

Found a problem?

If a link is dead, a source has been superseded, or a claim is not supported by what it points at, report it. Corrections are logged publicly at /corrections.